The Group underlines that it is necessary to secure the right balance between the inventors interests and the society's interest.
The Group states that only human stem cells which have been modified by an inventive process to get new characteristics for specific industrial application are patentable. The Group considers that cloning techniques aimed at obtaining human embryonic stem cells for therapeutic purposes should be excluded from patentability.
The report calls for the creation of an EU Registry of unmodified human stem cell lines that would include both embryonic stem cells and embryonic germ cells. The Registry would ensure transparency and facilitate access by the research community.



